Xenetic Biosciences, Inc.

menu

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Technology
    • Overview
    • DNase Platform
    • XCART™ Platform
    • PolyXen®
    • Publications
  • Product Pipeline
    • Overview
    • DNase
    • XCART™
    • PolyXen®
  • News & Media
    • Press Releases
    • Presentations
    • Multimedia
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
Investors

Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Information
    • Financials
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Proxy Materials
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

Jul 26, 2021

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

May 12, 2021

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

May 10, 2021

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

Mar 29, 2021

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 17, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

Mar 3, 2021

Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology

Feb 16, 2021

Xenetic Biosciences, Inc. to Present at NobleCon17

Jan 14, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Jan 5, 2021

Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Dec 14, 2020

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...13
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2023Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap